Risk Factors and Outcomes for Refeeding Syndrome in Acute Ischemic Stroke Patients

Risk Factors and Outcomes for Refeeding Syndrome in Acute Ischemic Stroke Patients | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Risk Factors and Outcomes for Refeeding Syndrome in Acute Ischemic Stroke Patients Shumin Chen, Dongchun Cai, Yuzheng Lai, Rong Chen, Jiangfeng He, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-1309641/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background Acute ischemic stroke (AIS) is more likely to develop refeeding syndrome (RFS) due to increased need for nutritional support when suffering dysfunction of consciousness and deglutition after stroke. This study aims to evaluate the occurrence, risk factors and outcomes of RFS in AIS patients. Methods This retrospective observational study, using the prospective stroke database from our hospital, included all consecutive AIS patients who received parenteral or enteral nutrition for more than 72 hours from January 1, 2019 to December 31, 2021. RFS was defined as occurrence of new onset hypophosphatemia within 72 hours after refeeding. Multiple logistic regression analysis was conducted to evaluate risk factors for RFS and relationship between RFS and 3-month modified Rankin Scale (mRS) score and 6-month mortility. Results Of 1038 patients were included in the study, 154 patients (14.8 %) developed RFS. We found that baseline National Institutes of Health Stroke Scale (NIHSS), nutritional risk screening (NRS) 2002, albumin < 30g/L and body mass index (BMI) 2 and 6-month mortility. Conclusion RFS is common in AIS patients and higher baseline NIHSS, higher NRS 2002 score, albumin < 30g/L and BMI < 18.5 kg/m 2 significantly increased the risk of RFS. Occurrence of RFS was significantly associated with higher 3-month mRS score and 6-month mortility. acute ischemic stroke refeeding syndrome risk factors NIHSS NRS 2002 Figures Figure 1 Figure 2 Introduction Refeeding syndrome (RFS) is usually defined as the fluid and electrolyte disturbance during refeeding after long-term malnutrition or starving, which can lead to failure of respiratory, cardiac, hepatic, hematological, neurologic and death. RFS can be induced by either enteral or parenteral nutrition support [1] . Acute ischemic stroke (AIS) patients are often subjected to malnutrition and require nutrition support due to dysfunction of deglutition, cognitive, consciousness and increased metabolic needs [2, 3] . Thus, AIS patients may be more likely to develop RFS. Moreover, RFS has been reported to be significantly associated with poor prognosis by increasing risk of mortality and continuing disability [4, 5] . Hence, it is of great significance to recognize high-risk patients of RFS and conduct sttict nutritional management for AIS patients. Hypophosphatemia is the main physiological characteristic for RFS and diagnostic criteria for RFS was commonly defined as new onset of hypophosphatemia with a fall of phosphate levels >0.16mmol/L to below 0.65mmol/L [6] . Incidence of RFS varies in different population and different feeding approaches. Based on the aforementioned definition, a recently randomized clinical trial found an incident of 34% in critically ill, invasive mechanically ventilated patients admitted for >7 days to a medical surgical intensive care unit (ICU) [7] . Another large retrospective cohort study conducted in our contrary found an incident of 17.1% in neurocritically ill patients [8] . However, incident of RFS in AIS patients were little reported and remain elucidated. Low body mass index (BMI), significant weight loss in the last 3-6 months, fasting or little food intake for more than 5 days, presence of electrolyte disturbance before refeeding and alcohol abuse were considered as risk factors for RFS in critically ill patients according to Guidelines for nutrition management of The European Society for Clinical Nutrition and Metabolism (ESPEN) [2] . Also, There are reports shows that age, low albumin, high nutritional intake, low insulin like growth factor-1, and enteral feedings should be taken into account for different populations [9, 10] . Another study showed that high malnutrition universal screening tool (MUST) and sequential organ failure assessment (SOFA) may increase risk of RFS in neurocritically ill patients and occurrence of RFS also acts as an independent risk factors for 6-month mortality [2, 8, 11, 12] . However, although AIS patients are high risk group for RFS, few investigations focus on AIS population to evaluate the incidence and risk factors of RFS. Relationship of RFS and AIS outcomes were also unclear. Here in this retrospective study, we aim to investigate incident and risk factors of RFS in AIS patients. Whether occurrence of RFS could negatively influence early and long-term outcomes of AIS was also assessed in this study. Methods Patients and study design We retrospectively reviewed consecutive patients diagnosed with AIS requiring enteral or parental nutritional support, admitted to stroke unit of Guangdong Hospital of Traditional Chinese and Western Medicine between January 1, 2019 and December 31, 2021. The inclusion criteria were as following: (1) acute ischemic stroke was demonstrated by diffusion-weighted imaging (DWI); (2) intracranial hemorrhage (ICH) was excluded by non-contrast computed temograph (CT); (3) receiving enteral or parental nutritional support for > 72 hours; (4) had serum phosphate records before refeeding and at 72±12 h after refeeding. Patients were excluded if they met one of the following criteria: (1) had incomplete data on nutrition provision; (2) were aged > 85 or < 18 years; (3) had serum phosphate < 0.65 mmol/L at admission; (4) were lost to follow-up; (5) had end-stage malignant diseases; (6) had complications for diabetic ketoacidosis or (7) had recent parathyroidectomy or were receiving renal replacement therapy, using phosphate binders, or undergoing the therapeutic hypothermia. This is a single-center, observational, retrospective cohort study using prospective collected data from our stroke database. Informed consent from patients or review board was waived because of its observational and retrospective properties. Management For Ais Patients All AIS patients admitted to our unit were treated in accordance with Chinese guidelines. Routine blood examinations, including blood routine tests, electrolytes, liver and kidney function, coagulation, troponin and C-reactive protein (CRP). etc, were conducted at admission and reviewed selectively according to abnormal initial results. Serum phosphate was required to reviewed at 72 hours after refeeding to early identify possible RFS. We performed strict nutrition management for each patient. NRS 2002 and MUST scores were conducted for all AIS patients to evaluate condition of nutrition at admission. Patients who are unable to eat on their own would receive individual nutritional support, mostly by enteral nutrition support, and total calorics per day were calculated and recorded regularly by professional nutritionist. Patients would receive repeated evaluation of mutritional conditions during hospitalization to adjust nutrition strategy in time. Diagnosis Of Rfs And Data Collection RFS was defined as new onset of hypophosphatemia within 72 hours after refeeding. Hypophosphatemia was defined as a drop of serum phosphate more than 0.16 mmol/L from admission to below 0.65 mmol/L. Based on this criterion, all included patients were divided into two groups, the RFS group and the non-RFS group. The following data were collected: age, gender, diabetes, coronary artery disease (CAD), previous stroke, smoking, serum glucose, blood pressure, blood electrolytes which including phosphate, potassium, sodium and magnesium, albumin, CRP, serum creatinine, total calorie per day for the first three days, baseline National Institutes of Health Stroke Scale (NIHSS) and mRS, modified Rankin Scale (mRS) at admission, nutritional risk screening (NRS) 2002 and MUST score at admission. 3-month mRS and 6-month mortality were evaluated by neurologists on outpatient appointment or by telephone follow-up. Statistical analysis Continuous variables were described as mean ±standard deviations or medians (and interquartile ranges) and categorical variables as number (percentage). The Kolmogorov–Smirnov test was used to test the normality of the data. Where quantitative data did not show a normal distribution, the Mann–Whitney rank sum test was used for group comparisons. Continuous, whereas categorical variables were compared with Fisher exact test or the χ 2 test. Candidate variables that had a P value less than 0.05 in the univariate analysis were drawn into multivariable logistic regression models to evaluate independent predictors for RFS. Ordinal logistic regression analysis was also conducted to evaluate the association between RFS and outcomes of AIS. An P value of 0.05 was considered statistically significant. All analysis was performed using SPSS 22.0 statistical software. Results Patients characteristics Of 1038 patients diagnosed with AIS and received nutritional support enrolled in the study, 154 patients developed RFS (14.8%). 684 patients were men (65.9%) and the average age was 64 years old in the population. The flow diagram of the analyzed cohort was shown in Figure 1 . There were no intergroup significant differences in the demographic characteristics and history diseases (Table 1 ). Baseline NIHSS score (median, 10 versus 6; P <0.001), MUST (median, 2 versus 1; P =0.012), NRS 2002 (median, 3 versus 4; P <0.001), and diastolic blood pressure (DBP) (85.8 ±11.3 versus 83.6 ±10.1; P =0.024) were significantly higher in the RFS group than the non-RFS group. For baseline blood tests, hemoglobin (median, 130 versus 120; P =0.035) and albumin (median, 35 versus 39; P =0.041) displayed lower and CRP (median, 10 versus 7; P =0.001) higher in the RFS group than non-RFS group. Patients in the RFS group received more calorie than that in the non-RFS group at the first day. Table 1 Baseline Characteristics of patients Characteristics RFS Group (n=154) Non-RFS Group (n=884) P value Demographics Age, y, mean±SD 65.2 ± 10.6 63.9 ± 12.4 0.064 Gender, male, n (%) 109 (70.8) 575 (65.0) 0.166 Medical History, n (%) Hypertension 97 (63.0) 556 (62.9) 0.983 Diabetes 51 (33.1) 223 (25.2) 0.040 * CAD 29 (18.8) 133 (15.0) 0.232 Previous stroke or TIA 28 (18.1) 221 (25.0) 0.067 Smoking 101 (65.6) 568 (64.2) 0.750 On admission SBP, mmHg, mean±SD 154.2 ± 15.9 153.9 ± 18.6 0.833 DBP, mmHg, mean±SD 85.8 ± 11.3 83.6 ± 10.1 0.024 * Serum glucose, mmol/L, mean±SD 6.9 ± 2.4 7.2 ± 1.7 0.137 Baseline NIHSS, median (IQR) 10 (4-13) 6 (3-9) < 0.001 * Baseline mRS, median (IQR) 3 (2-4) 3 (1-3) 0.056 NRS 2002, median (IQR) 3 (3-5) 2 (1-3) < 0.001 * MUST, median (IQR) 2 (2-2) 1 (0-1) 0.012 BMI, kg/m 2 , median (IQR) 18.9 (17.5-20.9) 20.4 (19.6-23.5) < 0.001 * Blood Test Hemoglobin, g/L, median (IQR) 130 (101-139) 140 (120-149) 0.035 * Albumin, g/L median (IQR) 35 (27-39) 39 (36-42) 0.041 * Creatinine, µmol/L, median (IQR) 76.4 (56.4-89.5) 80.2 (78.6-94.5) 0.067 CRP, mg/L, median (IQR) 10 (8-19) 7 (6-15) < 0.001 * BNP, pg/mL, median (IQR) 56 (34-94) 64 (45-95) 0.995 Phosphate, mmol/L, median (IQR) 1.03 (0.72-1.13) 1.05 (0.85-1.21) 0.189 Potassium, mmol/L, median (IQR) 3.91 (3.68-5.29) 4.25 (3.10-5.34) 0.306 Sodium, mmol/L, median (IQR) 141 (137-142) 139 (136-143) 0.978 Magnesium, mmol/L, median (IQR) 0.85 (0.73-0.94) 0.84 (0.72-0.95) 0.224 Caloric intakes within the first 72 hours Day 1, Kcal, median, (IQR) 550 (500-600) 500 (450-550) 0.034 * Day 2, Kcal, median, (IQR) 950 (950-1200) 1000 (950-1250) 0.463 Day 3, Kcal, median, (IQR) 1450 (1400-1600) 1500 (1500-1600) 0.443 Outcomes 7-day NIHSS changes, median, (IQR) 1 (0-3) 2 (1-4) 0.004 3-month mRS, median, (IQR) 3 (2-4) 2 (1-3) < 0.001 * 6-month mortality, n (%) 3 (1.9) 5 (0.6) 0.010 Risk Factors For Rfs In Ais Patients In multivariable logistic analysis, NIHSS score, mRS score and calorie intake at second day were included in Model A and NIHSS (OR, 2.123; 95% CI, 1.754-3.014; P =0.024) and NRS 2002 (OR, 1.987; 95% CI, 1.528-3.446; P < 0.001) were found significantly associated with occurrence of RFS in AIS patients (Table 2 ). In Model B, which included DBP, hemoglobin, albumin, CRP, diabetes and BMI, albumin < 30 g/L (compared to ≥ 30 g/L; OR, 1.594; 95% CI, 1.328-2.416; P = 0.025) and BMI <18.5 kg/m 2 (compared to ≥ 18.5 kg/m 2 ; OR, 1.346; 95% CI, 1.245-1.569; P = 0.045) were risk factors for RFS (Table 2 ). MUST were not included in the Model A because of its collinearity with NRS 2002. Table 2 Risk factors for RFS in AIS patients Risk factors OR (95% CI) P value Model A Day 1 caloric intake 1.057 (0.984-1.173) 0.541 NIHSS 2.123 (1.754-3.014) 0.024 NRS 2002 a 1.987 (1.528-3.446) < 0.001 * Model B Albumin < 30g/L 1.594 (1.328-2.416) 0.025 * BMI 90 mmHg 1.138 (0.894-1.226) 0.137 CRP > 10 mg/L 1.046 (0.556-1.109) 0.754 Diabetes 1.036 (0.826-1.124) 0.256 Anemia 0.789 (0.984-1.173) 0.541 Influence Of Rfs On Ais Patients RFS group patients had lower 7-day NIHSS promotion than that in the non-RFS group (median, 1 versus 2; P = 0.004) (Table 1 ). During the follow-up, 3-month mRS (median, 3 versus 2; P < 0.001) and 6-month mortality (1.9% versus 0.6%; p < 0.001) were significantly higher in the RFS group than the non-RFS group (Table 1 and Figure 2 ). Ordinal logistic regression analysis, after adusting confounders including age and baseline NIHSS, showed a significant association between RFS and both the mRS score of > 2 at 3 months (OR, 1.794; 95% CI, 1.378-2.564; P = 0.016) and mortality at 6 months (OR, 2.561; 95% CI, 2.245-3.649; P < 0.001) (Table 3 ). Table 3 Outcomes of RFS in AIS patients Outcomes OR 95% CI P Value 3-month mRS 1.794 1.378-2.564 0.016 * 6-month mortality 2.561 2.245-3.649 < 0.001 * Discussion RFS has grown to a research hotspot of multiple subjects in view of its prevalence and close relationship with disease outcomes. However, incidence and risk factors of RFS in AIS patients remains unclear and the its influence on stroke outcomes were rarely reported. Here in this study, we take the lead to specially focus on RFS in AIS population and found that there were 14.8% of AIS patients developing RFS. High NRS 2002 and NIHSS score, as well as albumin < 30 g/L and BMI 2 and 6-month mortality. The incidence of RFS in AIS patients in this current study was lower than other population in previous studies. By using the same definition of RFS, the incidence of RFS ranges from 34–45% in ICU patients as described by Olthof et al. and Hoffmann et al [7, 13] . However, with different definition, Flesher et al. found an even higher incidence of 80% in critically ill patients [14] . Thus, different definition and population may induce adverse occurrence rate of RFS. Our study included AIS patients, partly of which were mild stroke with better conditions of nutrition. Moreover, since 2019 when ESPEN guidelines for RFS prevention and treatment were public [2] , our stroke unit performed a calorie restriction combined with supplies of Centrum multi element during the first three days to prevent electrolyte disturbance for patients with high risk of malnutrition, which may decrease development of RFS and thus explain why we have lower incidence of RFS in AIS patients. Further studies with multi-subgroup analysis based on stroke severity and stroke subtypes are required to clarify the incidence of RFS in AIS patients. Many screening tools reflecting disease severity and nutrition status were found to be associated with development of RFS in critically ill patients, including SOFA, Acute Physiology and Chronic Health Evaluation II (APACHE II) and MUST [8] . In our study, we included multiple scoring systems and found that high NIHSS and NRS 2002 increased risk of RFS in AIS patients. NIHSS score is a universally accepted standardization to evaluate severity of acute ischemic stroke and higher NIHSS score indicates more extensive neurologic deficits, especially impairment of cognitive, consciousness and swallowing, and thus lead to metabolic disturbance [15] . In addition, NRS 2002 was suspected to be collinearity with MUST in previous study, which is further demonstrated in our study due to its comparative predictive value of RFS [8] . In terms of bio-metabolic markers, we identified albumin < 30g/L and BMI < 18.5 kg/m 2 as risk factors for RFS in AIS patients. Hypoalbuminemia is also reported to be relative to RFS in ICU patients because of its reflection of systemic nutritional condition and immune to variety of diseases [16] . Besides, low magnesium and low insulin-like growth factor-1 (ILGF-1) were considered as risk factors for RFS in ICU patients [17, 18] , which was not investigated in our study. We did not find a significant relationship of CRP with RFS. We assumed that high level of CRP was attached to RFS because the higher CRP manifests systemic inflammatory status, which may induce increased nutritional requirement and lead to malnutrition [16] . On this context, nutritional support, especially enteral support, may potentially cause acquired hypophosphatemia. Nevertheless, results in our study were in contrary to the hypothesis and the poor accuracy of CRP to recognize systemic inflammation may contributed to this result [19] . It is worthy to further assess whether other AIS-associated inflammatory factors or combination of CRP with other biomarkers is more sensitive to predict RFS in AIS. The sensitivity and accuracy of National Institute for Health and Care Excellence (NICE) criteria to predict RFS were only 78% and 38% respectively as reported in a previous study [20] . A modified NICE criteria described by Friedli, which includes multiple demonstrated risk factors, such as BMI, large loss of weight, drug use of acid-inhibitor and so on, was also reported to have low sensitivity of RFS prediction [21] . Hence, it is urgent to recognize relative risk factors for RFS and establish a comprehensive screening system reflecting both disease severity and nutritional status to facilitate RFS prediction. With regard to outcomes of RFS on AIS patients, RFS was detected to be an independent risk factor for 6-month mortality, which was concordant with a recent study focusing on NCU patients [8] . Also, results showed that RFS was significantly associated with a 3-month mRS of > 2. Poorer stroke outcomes may be attributed to hypophosphatemia that may directly induce secondary neuromuscular injury or aggravating neurologic ischemia through decreasing oxygen delivery of red blood cell [22–24] . Moreover, hypophosphatemia would lead to respiratory muscle dysfunction and potentially result to respiratory failure [25, 26] . All these pathologic changes ultimately lead to continuous neurologic disability and higher risk of death. The major strength of this study is that it is the first investigation to focus on RFS in AIS population and included multiple biochemical indicators and scoring systems to evaluate risk factors and outcomes of RFS. Our results may provide reliable reference for nutritional management. There are also limitations. First, it is a retrospective, single-center study and excluded those lost to follow-up or without serum phosphate at 72 hours. We could not deny the selection bias and residual confounding. However, our prospective collected database may partly compensate for the retrospective nature. Second, part of patients may develop RFS beyond 72 hours and were divided into the non-RFS group, which may underestimate the incidence of RFS. Third, due to the small number of RFS patients, multi-subgroup analysis on diverse stroke severity and stroke subtypes were not conducted to further clarify the prevalence and risk factors of RFS in AIS patients. A prospective, randomized cohort study was required to further verify results in this current study. Conclusion In conclusion, the present study suggests a high morbidity of RFS in AIS patients and high NRS 2002 score and NIHSS, as well as lower albumin and BMI were risk factors for RFS. Occurrence of RFS increase the risk of poorer neurologic outcome at 3-month and death at 6 months. Abbreviations NIHSS National Institutes of Health Stroke Scale NRS 2002 nutritional risk screening mRS modified Rankin Scale BMI body mass index ESPEN European Society for Clinical Nutrition and Metabolism MUST malnutrition universal screening tool SOFA sequential organ failure assessment CRP C-reactive protein CAD coronary artery disease APACHE II Physiology and Chronic Health Evaluation II NICE National Institute for Health and Care Excellence OR odds ratio. Declarations Availability of data and materials The datasets used and/or analysed during the current study available from the corresponding authors (HS) on reasonable request. Ethics approval and consent to participate all methods included in the current study were carried out in accordance with relevant guidelines and regulations. All experimental protocols were approved by the medical ethics committee of the Guangdong Hospital of Integrated Traditional Chinese and Western Medicine, Affiliated hospital of Traditonal Chinese University of Guangzhou. Written informed consents were obtained from all patients or their legal guardians. Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. Funding Not applicable. Authors' contributions SC designed the study and wrote the manuscript. DC and JH helped to collect the clinical data. RC and YL performed the statistical analysis. LZ and HS revised and approved the paper. Acknowledgement We thank all patients, caregivers, health care professionals, students and institutions who have contributed and collaborated in this study. Authors' information 1 Department of Neurology, Guangdong Hospital of Integrated Traditional Chinese and Western Medicine, Affiliated hospital of Traditonal Chinese University of Guangzhou, Foshan, Guangdong 518000, P.R. China; 2 Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China. References Mcknight C L, Newberry C, Sarav M, Martindale R, Hurt R, Daley B. Refeeding Syndrome in the Critically Ill: a Literature Review and Clinician's Guide [J]. Current gastroenterology reports, 2019, 21(11): 58.doi: 10.1007/s11894-019-0724-3 Singer P, Blaser A R, Berger M M, Alhazzani W, Calder P C, Casaer M P, et al. ESPEN guideline on clinical nutrition in the intensive care unit [J]. Clinical nutrition (Edinburgh, Scotland), 2019, 38(1): 48-79.doi: 10.1016/j.clnu.2018.08.037 Burgos R, Bretón I, Cereda E, Desport J C, Dziewas R, Genton L, et al. ESPEN guideline clinical nutrition in neurology [J]. Clinical nutrition (Edinburgh, Scotland), 2018, 37(1): 354-96.doi: 10.1016/j.clnu.2017.09.003 Kraaijenbrink B V, Lambers W M, Mathus-Vliegen E M, Siegert C E. Incidence of refeeding syndrome in internal medicine patients [J]. The Netherlands journal of medicine, 2016, 74(3): 116-21.doi: Friedli N, Stanga Z, Sobotka L, Culkin A, Kondrup J, Laviano A, et al. Revisiting the refeeding syndrome: Results of a systematic review [J]. Nutrition (Burbank, Los Angeles County, Calif), 2017, 35(151-60.doi: 10.1016/j.nut.2016.05.016 Doig G S, Simpson F, Heighes P T, Bellomo R, Chesher D, Caterson I D, et al. Restricted versus continued standard caloric intake during the management of refeeding syndrome in critically ill adults: a randomised, parallel-group, multicentre, single-blind controlled trial [J]. The Lancet Respiratory medicine, 2015, 3(12): 943-52.doi: 10.1016/s2213-2600(15)00418-x Olthof L E, Koekkoek W, Van Setten C, Kars J C N, Van Blokland D, Van Zanten A R H. Impact of caloric intake in critically ill patients with, and without, refeeding syndrome: A retrospective study [J]. Clinical nutrition (Edinburgh, Scotland), 2018, 37(5): 1609-17.doi: 10.1016/j.clnu.2017.08.001 Xiong R, Huang H, Wu Y, Wang S, Wang D, Ji Z, et al. Incidence and outcome of refeeding syndrome in neurocritically ill patients [J]. Clinical nutrition (Edinburgh, Scotland), 2020, 10.1016/j.clnu.2020.06.038 National Institute for Health and Care Excellence: Clinical Guidelines [M]. Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition. London; National Institute for Health and Care Excellence (UK) Copyright © NICE 2019. 2017. Stanga Z, Brunner A, Leuenberger M, Grimble R F, Shenkin A, Allison S P, et al. Nutrition in clinical practice-the refeeding syndrome: illustrative cases and guidelines for prevention and treatment [J]. European journal of clinical nutrition, 2008, 62(6): 687-94.doi: 10.1038/sj.ejcn.1602854 Kondrup J, Rasmussen H H, Hamberg O, Stanga Z. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials [J]. Clinical nutrition (Edinburgh, Scotland), 2003, 22(3): 321-36.doi: 10.1016/s0261-5614(02)00214-5 Md Ralib A, Mat Nor M B. Refeeding hypophosphataemia after enteral nutrition in a Malaysian intensive care unit: risk factors and outcome [J]. Asia Pacific journal of clinical nutrition, 2018, 27(2): 329-35.doi: 10.6133/apjcn.062017.09 Hoffmann M, Zemlin A E, Meyer W P, Erasmus R T. Hypophosphataemia at a large academic hospital in South Africa [J]. Journal of clinical pathology, 2008, 61(10): 1104-7.doi: 10.1136/jcp.2007.054940 Flesher M E, Archer K A, Leslie B D, Mccollom R A, Martinka G P. Assessing the metabolic and clinical consequences of early enteral feeding in the malnourished patient [J]. JPEN Journal of parenteral and enteral nutrition, 2005, 29(2): 108-17.doi: 10.1177/0148607105029002108 Heldner M R, Zubler C, Mattle H P, Schroth G, Weck A, Mono M L, et al. National Institutes of Health stroke scale score and vessel occlusion in 2152 patients with acute ischemic stroke [J]. Stroke, 2013, 44(4): 1153-7.doi: 10.1161/strokeaha.111.000604 Eckart A, Struja T, Kutz A, Baumgartner A, Baumgartner T, Zurfluh S, et al. Relationship of Nutritional Status, Inflammation, and Serum Albumin Levels During Acute Illness: A Prospective Study [J]. The American journal of medicine, 2020, 133(6): 713-22.e7.doi: 10.1016/j.amjmed.2019.10.031 Rio A, Whelan K, Goff L, Reidlinger D P, Smeeton N. Occurrence of refeeding syndrome in adults started on artificial nutrition support: prospective cohort study [J]. BMJ open, 2013, 3(1): 10.1136/bmjopen-2012-002173 Goyale A, Ashley S L, Taylor D R, Elnenaei M O, Alaghband-Zadeh J, Sherwood R A, et al. Predicting refeeding hypophosphataemia: insulin growth factor 1 (IGF-1) as a diagnostic biochemical marker for clinical practice [J]. Annals of clinical biochemistry, 2015, 52(Pt 1): 82-7.doi: 10.1177/0004563214523739 Del Giudice M, Gangestad S W. Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters [J]. Brain, behavior, and immunity, 2018, 70(61-75.doi: 10.1016/j.bbi.2018.02.013 Zeki S, Culkin A, Gabe S M, Nightingale J M. Refeeding hypophosphataemia is more common in enteral than parenteral feeding in adult in patients [J]. Clinical nutrition (Edinburgh, Scotland), 2011, 30(3): 365-8.doi: 10.1016/j.clnu.2010.12.001 Reber E, Friedli N, Vasiloglou M F, Schuetz P, Stanga Z. Management of Refeeding Syndrome in Medical Inpatients [J]. Journal of clinical medicine, 2019, 8(12): 10.3390/jcm8122202 Duhm J. Glycolysis in human erythrocytes containing elevated concentrations of 2, 3-P2-glycerate [J]. Biochimica et biophysica acta, 1975, 385(1): 68-80.doi: 10.1016/0304-4165(75)90075-6 Sharma S, Brugnara C, Betensky R A, Waikar S S. Reductions in red blood cell 2,3-diphosphoglycerate concentration during continuous renal replacment therapy [J]. Clinical journal of the American Society of Nephrology : CJASN, 2015, 10(1): 74-9.doi: 10.2215/cjn.02160214 Diringer M. Neurologic manifestations of major electrolyte abnormalities [J]. Handbook of clinical neurology, 2017, 141(705-13.doi: 10.1016/b978-0-444-63599-0.00038-7 Araujo Castro M, Vázquez Martínez C. The refeeding syndrome. Importance of phosphorus [J]. Medicina clinica, 2018, 150(12): 472-8.doi: 10.1016/j.medcli.2017.12.008 Bordejé Laguna M L. [Our great forgotten, chronic respiratory sufferers] [J]. Nutricion hospitalaria, 2017, 34(Suppl 1): 38-45.doi: 10.20960/nh.1238 Additional Declarations No competing interests reported. Supplementary Files Highlights.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-1309641","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":81024496,"identity":"767cceb2-9403-4594-9192-b60c7a9dae60","order_by":0,"name":"Shumin Chen","email":"","orcid":"","institution":"Guangdong Hospital of Integrated Traditional Chinese and Western Medicine, Affiliated hospital of Traditonal Chinese University of Guangzhou","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Shumin","middleName":"","lastName":"Chen","suffix":""},{"id":81024497,"identity":"dbe92b83-0d8f-4336-b78f-003600aa3ae0","order_by":1,"name":"Dongchun Cai","email":"","orcid":"","institution":"Guangdong Hospital of Integrated Traditional Chinese and Western Medicine, Affiliated hospital of Traditonal Chinese University of Guangzhou","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Dongchun","middleName":"","lastName":"Cai","suffix":""},{"id":81024498,"identity":"217cc242-e0f2-43aa-b7a7-9298d68a15d8","order_by":2,"name":"Yuzheng Lai","email":"","orcid":"","institution":"Guangdong Hospital of Integrated Traditional Chinese and Western Medicine, Affiliated hospital of Traditonal Chinese University of Guangzhou","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Yuzheng","middleName":"","lastName":"Lai","suffix":""},{"id":81024499,"identity":"4f73fb16-0b2d-4abe-8e6d-13518bd951e6","order_by":3,"name":"Rong Chen","email":"","orcid":"","institution":"Guangdong Hospital of Integrated Traditional Chinese and Western Medicine, Affiliated hospital of Traditonal Chinese University of Guangzhou","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Rong","middleName":"","lastName":"Chen","suffix":""},{"id":81024500,"identity":"6071f4b1-b012-4949-94b9-41171b76d720","order_by":4,"name":"Jiangfeng He","email":"","orcid":"","institution":"Guangdong Hospital of Integrated Traditional Chinese and Western Medicine, Affiliated hospital of Traditonal Chinese University of Guangzhou","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Jiangfeng","middleName":"","lastName":"He","suffix":""},{"id":81024501,"identity":"da3c0243-12e6-493e-bb91-22732e8d4859","order_by":5,"name":"Liang Zhou","email":"","orcid":"","institution":"Nanfang Hospital, Southern Medical University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Liang","middleName":"","lastName":"Zhou","suffix":""},{"id":81024502,"identity":"c74d446e-dc9e-4f17-a5c2-ebfb88a48d55","order_by":6,"name":"Sun Hao","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA7ElEQVRIiWNgGAWjYBAC9gYGNiiTB4grJOTkCWnhOYCi5YyFsWEDSVoY2yoSGQ4Q0sJ/9tjDn22H7Q1u9x788HGeRAJjA/PDRzfwaZHISzeQbDucuOHOuWTJmdsk8tgZ2IyNc/BosZfgMZMwbDucYHAjx0Cad5tEMWMDD5s0Pi08/GfMJBJBDruRY/ybd45EYsMBQloYcswkDrYdZtxwI8dMmreBGC0SOWaSDefSE2cCtVjOOCZhbNhMwC8gh0n+KLO25wM67MaHmjo5efbmh4/xaQEDRrZmJB4zIeVg8KeOKGWjYBSMglEwQgEA05lJW0bcmpwAAAAASUVORK5CYII=","orcid":"","institution":"Guangdong Hospital of Integrated Traditional Chinese and Western Medicine, Affiliated hospital of Traditonal Chinese University of Guangzhou","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Sun","middleName":"","lastName":"Hao","suffix":""}],"badges":[],"createdAt":"2022-01-29 13:59:08","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-1309641/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-1309641/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":17951542,"identity":"4fde1f6c-e561-4f76-87e3-f90f3b20a2f0","added_by":"auto","created_at":"2022-02-04 21:02:19","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":19028,"visible":true,"origin":"","legend":"\u003cp\u003e\t\u003cstrong\u003eSelection process of patients.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Onlinefloatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-1309641/v1/21ad58ca0f1a3bb796ca0372.png"},{"id":17951541,"identity":"0940f95a-b198-43f6-a4bb-2926e41702f5","added_by":"auto","created_at":"2022-02-04 21:02:19","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":15245,"visible":true,"origin":"","legend":"\u003cp\u003e\t\u003cstrong\u003e3-month mRS of AIS patients in RFS group and non-RFS group.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Onlinefloatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-1309641/v1/04affb63f0aa7b093b3f0bda.png"},{"id":18966041,"identity":"70648b42-ec83-4d71-b913-2db45d709226","added_by":"auto","created_at":"2022-03-08 06:59:24","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":426016,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-1309641/v1/5f3dc15e-8d35-4d0a-b5ee-36ddf3924fb9.pdf"},{"id":17951780,"identity":"3b7c95e7-abc2-4fea-80bc-618b8f4ab2f3","added_by":"auto","created_at":"2022-02-04 21:05:19","extension":"docx","order_by":5,"title":"","display":"","copyAsset":false,"role":"supplement","size":16258,"visible":true,"origin":"","legend":"","description":"","filename":"Highlights.docx","url":"https://assets-eu.researchsquare.com/files/rs-1309641/v1/112f7091aa8975491006cad1.docx"}],"financialInterests":"No competing interests reported.","formattedTitle":"\u003cp\u003eRisk Factors and Outcomes for Refeeding Syndrome in Acute Ischemic Stroke Patients\u003c/p\u003e","fulltext":[{"header":"Introduction","content":"\u003cp\u003eRefeeding syndrome (RFS) is usually defined as the fluid and electrolyte disturbance during refeeding after long-term malnutrition or starving, which can lead to failure of respiratory, cardiac, hepatic, hematological, neurologic and death. RFS can be induced by either enteral or parenteral nutrition support \u003csup\u003e[1]\u003c/sup\u003e. Acute ischemic stroke (AIS) patients are often subjected to malnutrition and require nutrition support due to dysfunction of deglutition, cognitive, consciousness and increased metabolic needs \u003csup\u003e[2, 3]\u003c/sup\u003e. Thus, AIS patients may be more likely to develop RFS. Moreover, RFS has been reported to be significantly associated with poor prognosis by increasing risk of mortality and continuing disability \u003csup\u003e[4, 5]\u003c/sup\u003e. Hence, it is of great significance to recognize high-risk patients of RFS and conduct sttict nutritional management for AIS patients.\u003c/p\u003e \u003cp\u003eHypophosphatemia is the main physiological characteristic for RFS and diagnostic criteria for RFS was commonly defined as new onset of hypophosphatemia with a fall of phosphate levels \u0026gt;0.16mmol/L to below 0.65mmol/L \u003csup\u003e[6]\u003c/sup\u003e. Incidence of RFS varies in different population and different feeding approaches. Based on the aforementioned definition, a recently randomized clinical trial found an incident of 34% in critically ill, invasive mechanically ventilated patients admitted for \u0026gt;7 days to a medical surgical intensive care unit (ICU) \u003csup\u003e[7]\u003c/sup\u003e. Another large retrospective cohort study conducted in our contrary found an incident of 17.1% in neurocritically ill patients \u003csup\u003e[8]\u003c/sup\u003e. However, incident of RFS in AIS patients were little reported and remain elucidated. Low body mass index (BMI), significant weight loss in the last 3-6 months, fasting or little food intake for more than 5 days, presence of electrolyte disturbance before refeeding and alcohol abuse were considered as risk factors for RFS in critically ill patients according to Guidelines for nutrition management of The European Society for Clinical Nutrition and Metabolism (ESPEN) \u003csup\u003e[2]\u003c/sup\u003e. Also, There are reports shows that age, low albumin, high nutritional intake, low insulin like growth factor-1, and enteral feedings should be taken into account for different populations \u003csup\u003e[9, 10]\u003c/sup\u003e. Another study showed that high malnutrition universal screening tool (MUST) and sequential organ failure assessment (SOFA) may increase risk of RFS in neurocritically ill patients and occurrence of RFS also acts as an independent risk factors for 6-month mortality \u003csup\u003e[2, 8, 11, 12]\u003c/sup\u003e. However, although AIS patients are high risk group for RFS, few investigations focus on AIS population to evaluate the incidence and risk factors of RFS. Relationship of RFS and AIS outcomes were also unclear.\u003c/p\u003e \u003cp\u003eHere in this retrospective study, we aim to investigate incident and risk factors of RFS in AIS patients. Whether occurrence of RFS could negatively influence early and long-term outcomes of AIS was also assessed in this study.\u003c/p\u003e"},{"header":"Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003ePatients and study design\u003c/h2\u003e \u003cp\u003eWe retrospectively reviewed consecutive patients diagnosed with AIS requiring enteral or parental nutritional support, admitted to stroke unit of Guangdong Hospital of Traditional Chinese and Western Medicine between January 1, 2019 and December 31, 2021. The inclusion criteria were as following: (1) acute ischemic stroke was demonstrated by diffusion-weighted imaging (DWI); (2) intracranial hemorrhage (ICH) was excluded by non-contrast computed temograph (CT); (3) receiving enteral or parental nutritional support for \u0026gt; 72 hours; (4) had serum phosphate records before refeeding and at 72\u0026plusmn;12 h after refeeding. Patients were excluded if they met one of the following criteria: (1) had incomplete data on nutrition provision; (2) were aged \u0026gt; 85 or \u0026lt; 18 years; (3) had serum phosphate \u0026lt; 0.65 mmol/L at admission; (4) were lost to follow-up; (5) had end-stage malignant diseases; (6) had complications for diabetic ketoacidosis or (7) had recent parathyroidectomy or were receiving renal replacement therapy, using phosphate binders, or undergoing the therapeutic hypothermia.\u003c/p\u003e \u003cp\u003eThis is a single-center, observational, retrospective cohort study using prospective collected data from our stroke database. Informed consent from patients or review board was waived because of its observational and retrospective properties.\u003c/p\u003e \u003c/div\u003e\n\u003ch2\u003eManagement For Ais Patients\u003c/h2\u003e\n\u003cp\u003e All AIS patients admitted to our unit were treated in accordance with Chinese guidelines. Routine blood examinations, including blood routine tests, electrolytes, liver and kidney function, coagulation, troponin and C-reactive protein (CRP). etc, were conducted at admission and reviewed selectively according to abnormal initial results. Serum phosphate was required to reviewed at 72 hours after refeeding to early identify possible RFS. We performed strict nutrition management for each patient. NRS 2002 and MUST scores were conducted for all AIS patients to evaluate condition of nutrition at admission. Patients who are unable to eat on their own would receive individual nutritional support, mostly by enteral nutrition support, and total calorics per day were calculated and recorded regularly by professional nutritionist. Patients would receive repeated evaluation of mutritional conditions during hospitalization to adjust nutrition strategy in time.\u003c/p\u003e\n\u003ch2\u003eDiagnosis Of Rfs And Data Collection\u003c/h2\u003e\n\u003cp\u003eRFS was defined as new onset of hypophosphatemia within 72 hours after refeeding. Hypophosphatemia was defined as a drop of serum phosphate more than 0.16 mmol/L from admission to below 0.65 mmol/L. Based on this criterion, all included patients were divided into two groups, the RFS group and the non-RFS group. The following data were collected: age, gender, diabetes, coronary artery disease (CAD), previous stroke, smoking, serum glucose, blood pressure, blood electrolytes which including phosphate, potassium, sodium and magnesium, albumin, CRP, serum creatinine, total calorie per day for the first three days, baseline National Institutes of Health Stroke Scale (NIHSS) and mRS, modified Rankin Scale (mRS) at admission, nutritional risk screening (NRS) 2002 and MUST score at admission. 3-month mRS and 6-month mortality were evaluated by neurologists on outpatient appointment or by telephone follow-up.\u003c/p\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analysis\u003c/h2\u003e \u003cp\u003eContinuous variables were described as mean \u0026plusmn;standard deviations or medians (and interquartile ranges) and categorical variables as number (percentage). The Kolmogorov\u0026ndash;Smirnov test was used to test the normality of the data. Where quantitative data did not show a normal distribution, the Mann\u0026ndash;Whitney rank sum test was used for group comparisons. Continuous, whereas categorical variables were compared with Fisher exact test or the χ 2 test. Candidate variables that had a \u003cem\u003eP\u003c/em\u003e value less than 0.05 in the univariate analysis were drawn into multivariable logistic regression models to evaluate independent predictors for RFS. Ordinal logistic regression analysis was also conducted to evaluate the association between RFS and outcomes of AIS. An \u003cem\u003eP\u003c/em\u003e value of 0.05 was considered statistically significant. All analysis was performed using SPSS 22.0 statistical software.\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003ePatients characteristics\u003c/h2\u003e \u003cp\u003eOf 1038 patients diagnosed with AIS and received nutritional support enrolled in the study, 154 patients developed RFS (14.8%). 684 patients were men (65.9%) and the average age was 64 years old in the population. The flow diagram of the analyzed cohort was shown in Figure \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e. There were no intergroup significant differences in the demographic characteristics and history diseases (Table \u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). Baseline NIHSS score (median, 10 versus 6; \u003cem\u003eP\u003c/em\u003e\u0026lt;0.001), MUST (median, 2 versus 1; \u003cem\u003eP\u003c/em\u003e=0.012), NRS 2002 (median, 3 versus 4; \u003cem\u003eP\u003c/em\u003e\u0026lt;0.001), and diastolic blood pressure (DBP) (85.8 \u0026plusmn;11.3 versus 83.6 \u0026plusmn;10.1; \u003cem\u003eP\u003c/em\u003e=0.024) were significantly higher in the RFS group than the non-RFS group. For baseline blood tests, hemoglobin (median, 130 versus 120; \u003cem\u003eP\u003c/em\u003e=0.035) and albumin (median, 35 versus 39; \u003cem\u003eP\u003c/em\u003e=0.041) displayed lower and CRP (median, 10 versus 7; \u003cem\u003eP\u003c/em\u003e=0.001) higher in the RFS group than non-RFS group. Patients in the RFS group received more calorie than that in the non-RFS group at the first day.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eBaseline Characteristics of patients\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCharacteristics\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRFS Group\u003c/p\u003e \u003cp\u003e(n=154)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNon-RFS Group\u003c/p\u003e \u003cp\u003e(n=884)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cem\u003eP\u003c/em\u003e value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDemographics\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAge, y, mean\u0026plusmn;SD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e65.2 \u0026plusmn; 10.6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e63.9 \u0026plusmn; 12.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.064\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGender, male, n (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e109 (70.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e575 (65.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.166\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMedical History, n (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHypertension\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e97 (63.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e556 (62.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.983\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDiabetes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e51 (33.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e223 (25.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.040\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCAD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e29 (18.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e133 (15.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.232\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePrevious stroke or TIA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e28 (18.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e221 (25.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.067\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSmoking\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e101 (65.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e568 (64.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.750\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOn admission\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSBP, mmHg, mean\u0026plusmn;SD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e154.2 \u0026plusmn; 15.9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e153.9 \u0026plusmn; 18.6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.833\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDBP, mmHg, mean\u0026plusmn;SD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e85.8 \u0026plusmn; 11.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e83.6 \u0026plusmn; 10.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.024\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSerum glucose, mmol/L, mean\u0026plusmn;SD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e6.9 \u0026plusmn; 2.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e7.2 \u0026plusmn; 1.7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.137\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBaseline NIHSS, median (IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e10 (4-13)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6 (3-9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt; 0.001\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBaseline mRS, median (IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3 (2-4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3 (1-3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.056\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNRS 2002, median (IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3 (3-5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2 (1-3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt; 0.001\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMUST, median (IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (2-2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (0-1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.012\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBMI, kg/m\u003csup\u003e2\u003c/sup\u003e, median (IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e18.9 (17.5-20.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e20.4 (19.6-23.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt; 0.001\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBlood Test\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHemoglobin, g/L, median (IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e130 (101-139)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e140 (120-149)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.035\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAlbumin, g/L median (IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e35 (27-39)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e39 (36-42)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.041\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCreatinine, \u0026micro;mol/L, median (IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e76.4 (56.4-89.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e80.2 (78.6-94.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.067\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCRP, mg/L, median (IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e10 (8-19)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e7 (6-15)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt; 0.001\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBNP, pg/mL, median (IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e56 (34-94)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e64 (45-95)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.995\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePhosphate, mmol/L, median (IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.03 (0.72-1.13)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.05 (0.85-1.21)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.189\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePotassium, mmol/L, median (IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3.91 (3.68-5.29)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4.25 (3.10-5.34)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.306\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSodium, mmol/L, median (IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e141 (137-142)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e139 (136-143)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.978\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMagnesium, mmol/L, median (IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0.85 (0.73-0.94)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0.84 (0.72-0.95)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.224\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCaloric intakes within the first 72 hours\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDay 1, Kcal, median, (IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e550 (500-600)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e500 (450-550)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.034\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDay 2, Kcal, median, (IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e950 (950-1200)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1000 (950-1250)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.463\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDay 3, Kcal, median, (IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1450 (1400-1600)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1500 (1500-1600)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.443\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOutcomes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e7-day NIHSS changes, median, (IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (0-3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2 (1-4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.004\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3-month mRS, median, (IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3 (2-4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2 (1-3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt; 0.001\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e6-month mortality, n (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3 (1.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5 (0.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.010\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e\n\u003ch2\u003eRisk Factors For Rfs In Ais Patients\u003c/h2\u003e\n\u003cp\u003eIn multivariable logistic analysis, NIHSS score, mRS score and calorie intake at second day were included in Model A and NIHSS (OR, 2.123; 95% CI, 1.754-3.014; \u003cem\u003eP\u003c/em\u003e =0.024) and NRS 2002 (OR, 1.987; 95% CI, 1.528-3.446; \u003cem\u003eP\u003c/em\u003e\u0026lt; 0.001) were found significantly associated with occurrence of RFS in AIS patients (Table \u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e). In Model B, which included DBP, hemoglobin, albumin, CRP, diabetes and BMI, albumin \u0026lt; 30 g/L (compared to \u0026ge; 30 g/L; OR, 1.594; 95% CI, 1.328-2.416; \u003cem\u003eP\u003c/em\u003e= 0.025) and BMI \u0026lt;18.5 kg/m\u003csup\u003e2\u003c/sup\u003e (compared to \u0026ge; 18.5 kg/m\u003csup\u003e2\u003c/sup\u003e; OR, 1.346; 95% CI, 1.245-1.569; \u003cem\u003eP\u003c/em\u003e= 0.045) were risk factors for RFS (Table \u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e). MUST were not included in the Model A because of its collinearity with NRS 2002.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eRisk factors for RFS in AIS patients\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRisk factors\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOR (95% CI)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e\u003cem\u003eP\u003c/em\u003e value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"4\" nameend=\"c4\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eModel A\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDay 1 caloric intake\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.057 (0.984-1.173)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e0.541\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNIHSS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2.123 (1.754-3.014)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e0.024\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNRS 2002\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.987 (1.528-3.446)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e\u0026lt; 0.001\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eModel B\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAlbumin \u0026lt; 30g/L\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.594 (1.328-2.416)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e0.025\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBMI \u0026lt; 18.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.346 (1.245-1.569)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e0.045\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDBP \u0026gt; 90 mmHg\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.138 (0.894-1.226)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e0.137\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCRP \u0026gt; 10 mg/L\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.046 (0.556-1.109)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e0.754\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDiabetes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.036 (0.826-1.124)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e0.256\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAnemia\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0.789 (0.984-1.173)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e0.541\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e\n\u003ch2\u003eInfluence Of Rfs On Ais Patients\u003c/h2\u003e\n\u003cp\u003eRFS group patients had lower 7-day NIHSS promotion than that in the non-RFS group (median, 1 versus 2; \u003cem\u003eP\u003c/em\u003e= 0.004) (Table \u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). During the follow-up, 3-month mRS (median, 3 versus 2; \u003cem\u003eP\u003c/em\u003e\u0026lt; 0.001) and 6-month mortality (1.9% versus 0.6%; p \u0026lt; 0.001) were significantly higher in the RFS group than the non-RFS group (Table \u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e and Figure \u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e). Ordinal logistic regression analysis, after adusting confounders including age and baseline NIHSS, showed a significant association between RFS and both the mRS score of \u0026gt; 2 at 3 months (OR, 1.794; 95% CI, 1.378-2.564; \u003cem\u003eP\u003c/em\u003e= 0.016) and mortality at 6 months (OR, 2.561; 95% CI, 2.245-3.649; \u003cem\u003eP\u003c/em\u003e\u0026lt; 0.001) (Table \u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eOutcomes of RFS in AIS patients\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOutcomes\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOR\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003e95% CI\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cem\u003eP\u003c/em\u003e Value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3-month mRS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.794\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.378-2.564\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.016\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e6-month mortality\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2.561\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.245-3.649\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt; 0.001\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eRFS has grown to a research hotspot of multiple subjects in view of its prevalence and close relationship with disease outcomes. However, incidence and risk factors of RFS in AIS patients remains unclear and the its influence on stroke outcomes were rarely reported. Here in this study, we take the lead to specially focus on RFS in AIS population and found that there were 14.8% of AIS patients developing RFS. High NRS 2002 and NIHSS score, as well as albumin \u0026lt; 30 g/L and BMI \u0026lt; 18.5 kg/m\u003csup\u003e2\u003c/sup\u003e were risk factors for RFS in AIS patients. Also, results showed that o RFS increased risk of poorer stroke outcomes with higher proportion of 3-month mRS of \u0026gt;2 and 6-month mortality.\u003c/p\u003e \u003cp\u003eThe incidence of RFS in AIS patients in this current study was lower than other population in previous studies. By using the same definition of RFS, the incidence of RFS ranges from 34\u0026ndash;45% in ICU patients as described by Olthof et al. and Hoffmann et al \u003csup\u003e[7, 13]\u003c/sup\u003e. However, with different definition, Flesher et al. found an even higher incidence of 80% in critically ill patients\u003csup\u003e[14]\u003c/sup\u003e. Thus, different definition and population may induce adverse occurrence rate of RFS. Our study included AIS patients, partly of which were mild stroke with better conditions of nutrition. Moreover, since 2019 when ESPEN guidelines for RFS prevention and treatment were public \u003csup\u003e[2]\u003c/sup\u003e, our stroke unit performed a calorie restriction combined with supplies of Centrum multi element during the first three days to prevent electrolyte disturbance for patients with high risk of malnutrition, which may decrease development of RFS and thus explain why we have lower incidence of RFS in AIS patients. Further studies with multi-subgroup analysis based on stroke severity and stroke subtypes are required to clarify the incidence of RFS in AIS patients.\u003c/p\u003e \u003cp\u003eMany screening tools reflecting disease severity and nutrition status were found to be associated with development of RFS in critically ill patients, including SOFA, Acute Physiology and Chronic Health Evaluation II (APACHE II) and MUST \u003csup\u003e[8]\u003c/sup\u003e. In our study, we included multiple scoring systems and found that high NIHSS and NRS 2002 increased risk of RFS in AIS patients. NIHSS score is a universally accepted standardization to evaluate severity of acute ischemic stroke and higher NIHSS score indicates more extensive neurologic deficits, especially impairment of cognitive, consciousness and swallowing, and thus lead to metabolic disturbance \u003csup\u003e[15]\u003c/sup\u003e. In addition, NRS 2002 was suspected to be collinearity with MUST in previous study, which is further demonstrated in our study due to its comparative predictive value of RFS \u003csup\u003e[8]\u003c/sup\u003e. In terms of bio-metabolic markers, we identified albumin \u0026lt; 30g/L and BMI \u0026lt; 18.5 kg/m\u003csup\u003e2\u003c/sup\u003e as risk factors for RFS in AIS patients. Hypoalbuminemia is also reported to be relative to RFS in ICU patients because of its reflection of systemic nutritional condition and immune to variety of diseases \u003csup\u003e[16]\u003c/sup\u003e. Besides, low magnesium and low insulin-like growth factor-1 (ILGF-1) were considered as risk factors for RFS in ICU patients \u003csup\u003e[17, 18]\u003c/sup\u003e, which was not investigated in our study. We did not find a significant relationship of CRP with RFS. We assumed that high level of CRP was attached to RFS because the higher CRP manifests systemic inflammatory status, which may induce increased nutritional requirement and lead to malnutrition \u003csup\u003e[16]\u003c/sup\u003e. On this context, nutritional support, especially enteral support, may potentially cause acquired hypophosphatemia. Nevertheless, results in our study were in contrary to the hypothesis and the poor accuracy of CRP to recognize systemic inflammation may contributed to this result \u003csup\u003e[19]\u003c/sup\u003e. It is worthy to further assess whether other AIS-associated inflammatory factors or combination of CRP with other biomarkers is more sensitive to predict RFS in AIS.\u003c/p\u003e \u003cp\u003eThe sensitivity and accuracy of National Institute for Health and Care Excellence (NICE) criteria to predict RFS were only 78% and 38% respectively as reported in a previous study \u003csup\u003e[20]\u003c/sup\u003e. A modified NICE criteria described by Friedli, which includes multiple demonstrated risk factors, such as BMI, large loss of weight, drug use of acid-inhibitor and so on, was also reported to have low sensitivity of RFS prediction \u003csup\u003e[21]\u003c/sup\u003e. Hence, it is urgent to recognize relative risk factors for RFS and establish a comprehensive screening system reflecting both disease severity and nutritional status to facilitate RFS prediction.\u003c/p\u003e \u003cp\u003eWith regard to outcomes of RFS on AIS patients, RFS was detected to be an independent risk factor for 6-month mortality, which was concordant with a recent study focusing on NCU patients \u003csup\u003e[8]\u003c/sup\u003e. Also, results showed that RFS was significantly associated with a 3-month mRS of \u0026gt; 2. Poorer stroke outcomes may be attributed to hypophosphatemia that may directly induce secondary neuromuscular injury or aggravating neurologic ischemia through decreasing oxygen delivery of red blood cell \u003csup\u003e[22\u0026ndash;24]\u003c/sup\u003e. Moreover, hypophosphatemia would lead to respiratory muscle dysfunction and potentially result to respiratory failure \u003csup\u003e[25, 26]\u003c/sup\u003e. All these pathologic changes ultimately lead to continuous neurologic disability and higher risk of death.\u003c/p\u003e \u003cp\u003eThe major strength of this study is that it is the first investigation to focus on RFS in AIS population and included multiple biochemical indicators and scoring systems to evaluate risk factors and outcomes of RFS. Our results may provide reliable reference for nutritional management. There are also limitations. First, it is a retrospective, single-center study and excluded those lost to follow-up or without serum phosphate at 72 hours. We could not deny the selection bias and residual confounding. However, our prospective collected database may partly compensate for the retrospective nature. Second, part of patients may develop RFS beyond 72 hours and were divided into the non-RFS group, which may underestimate the incidence of RFS. Third, due to the small number of RFS patients, multi-subgroup analysis on diverse stroke severity and stroke subtypes were not conducted to further clarify the prevalence and risk factors of RFS in AIS patients. A prospective, randomized cohort study was required to further verify results in this current study.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eIn conclusion, the present study suggests a high morbidity of RFS in AIS patients and high NRS 2002 score and NIHSS, as well as lower albumin and BMI were risk factors for RFS. Occurrence of RFS increase the risk of poorer neurologic outcome at 3-month and death at 6 months.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cdiv class=\"DefinitionList\"\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eNIHSS\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eNational Institutes of Health Stroke Scale\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eNRS 2002\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003enutritional risk screening\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003emRS\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003emodified Rankin Scale\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eBMI\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003ebody mass index\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eESPEN\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eEuropean Society for Clinical Nutrition and Metabolism\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eMUST\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003emalnutrition universal screening tool\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eSOFA\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003esequential organ failure assessment\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eCRP\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eC-reactive protein\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eCAD\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003ecoronary artery disease\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eAPACHE II\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003ePhysiology and Chronic Health Evaluation II\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eNICE\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eNational Institute for Health and Care Excellence\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eOR\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eodds ratio.\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003c/div\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe datasets used and/or analysed during the current study available from the corresponding authors (HS) on reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eall methods included in the current study were carried out in accordance with relevant guidelines and regulations. All experimental protocols were approved by the medical ethics committee of the Guangdong Hospital of Integrated Traditional Chinese and Western Medicine, Affiliated hospital of Traditonal Chinese University of Guangzhou. \u0026nbsp;Written informed consents were obtained from all patients or their legal guardians.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that they have no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026apos; contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSC designed the study and wrote the manuscript. DC and JH helped to collect the clinical data. RC and YL performed the statistical analysis. LZ and HS revised and approved the paper.\u003cbr\u003e \u003cstrong\u003eAcknowledgement\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eWe thank all patients, caregivers, health care professionals, students and institutions who have contributed and collaborated in this study.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026apos; information\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e1\u003c/sup\u003e Department of Neurology, Guangdong Hospital of Integrated Traditional Chinese and Western Medicine, Affiliated hospital of Traditonal Chinese University of Guangzhou, Foshan, Guangdong 518000, P.R. China; \u003csup\u003e2\u003c/sup\u003e Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003e Mcknight C L, Newberry C, Sarav M, Martindale R, Hurt R, Daley B. Refeeding Syndrome in the Critically Ill: a Literature Review and Clinician's Guide [J]. Current gastroenterology reports, 2019, 21(11): 58.doi: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s11894-019-0724-3\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Singer P, Blaser A R, Berger M M, Alhazzani W, Calder P C, Casaer M P, et al. ESPEN guideline on clinical nutrition in the intensive care unit [J]. Clinical nutrition (Edinburgh, Scotland), 2019, 38(1): 48-79.doi: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.clnu.2018.08.037\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Burgos R, Bret\u0026oacute;n I, Cereda E, Desport J C, Dziewas R, Genton L, et al. ESPEN guideline clinical nutrition in neurology [J]. Clinical nutrition (Edinburgh, Scotland), 2018, 37(1): 354-96.doi: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.clnu.2017.09.003\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Kraaijenbrink B V, Lambers W M, Mathus-Vliegen E M, Siegert C E. Incidence of refeeding syndrome in internal medicine patients [J]. The Netherlands journal of medicine, 2016, 74(3): 116-21.doi:\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Friedli N, Stanga Z, Sobotka L, Culkin A, Kondrup J, Laviano A, et al. Revisiting the refeeding syndrome: Results of a systematic review [J]. Nutrition (Burbank, Los Angeles County, Calif), 2017, 35(151-60.doi: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.nut.2016.05.016\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Doig G S, Simpson F, Heighes P T, Bellomo R, Chesher D, Caterson I D, et al. Restricted versus continued standard caloric intake during the management of refeeding syndrome in critically ill adults: a randomised, parallel-group, multicentre, single-blind controlled trial [J]. The Lancet Respiratory medicine, 2015, 3(12): 943-52.doi: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/s2213-2600(15)00418-x\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Olthof L E, Koekkoek W, Van Setten C, Kars J C N, Van Blokland D, Van Zanten A R H. Impact of caloric intake in critically ill patients with, and without, refeeding syndrome: A retrospective study [J]. Clinical nutrition (Edinburgh, Scotland), 2018, 37(5): 1609-17.doi: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.clnu.2017.08.001\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Xiong R, Huang H, Wu Y, Wang S, Wang D, Ji Z, et al. Incidence and outcome of refeeding syndrome in neurocritically ill patients [J]. Clinical nutrition (Edinburgh, Scotland), 2020, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.clnu.2020.06.038\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e National Institute for Health and Care Excellence: Clinical Guidelines [M]. Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition. London; National Institute for Health and Care Excellence (UK)\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCopyright \u0026copy; NICE 2019. 2017.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Stanga Z, Brunner A, Leuenberger M, Grimble R F, Shenkin A, Allison S P, et al. Nutrition in clinical practice-the refeeding syndrome: illustrative cases and guidelines for prevention and treatment [J]. European journal of clinical nutrition, 2008, 62(6): 687-94.doi: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/sj.ejcn.1602854\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Kondrup J, Rasmussen H H, Hamberg O, Stanga Z. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials [J]. Clinical nutrition (Edinburgh, Scotland), 2003, 22(3): 321-36.doi: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/s0261-5614(02)00214-5\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Md Ralib A, Mat Nor M B. Refeeding hypophosphataemia after enteral nutrition in a Malaysian intensive care unit: risk factors and outcome [J]. Asia Pacific journal of clinical nutrition, 2018, 27(2): 329-35.doi: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.6133/apjcn.062017.09\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Hoffmann M, Zemlin A E, Meyer W P, Erasmus R T. Hypophosphataemia at a large academic hospital in South Africa [J]. Journal of clinical pathology, 2008, 61(10): 1104-7.doi: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1136/jcp.2007.054940\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Flesher M E, Archer K A, Leslie B D, Mccollom R A, Martinka G P. Assessing the metabolic and clinical consequences of early enteral feeding in the malnourished patient [J]. JPEN Journal of parenteral and enteral nutrition, 2005, 29(2): 108-17.doi: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1177/0148607105029002108\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Heldner M R, Zubler C, Mattle H P, Schroth G, Weck A, Mono M L, et al. National Institutes of Health stroke scale score and vessel occlusion in 2152 patients with acute ischemic stroke [J]. Stroke, 2013, 44(4): 1153-7.doi: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1161/strokeaha.111.000604\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Eckart A, Struja T, Kutz A, Baumgartner A, Baumgartner T, Zurfluh S, et al. Relationship of Nutritional Status, Inflammation, and Serum Albumin Levels During Acute Illness: A Prospective Study [J]. The American journal of medicine, 2020, 133(6): 713-22.e7.doi: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.amjmed.2019.10.031\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Rio A, Whelan K, Goff L, Reidlinger D P, Smeeton N. Occurrence of refeeding syndrome in adults started on artificial nutrition support: prospective cohort study [J]. BMJ open, 2013, 3(1): \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1136/bmjopen-2012-002173\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Goyale A, Ashley S L, Taylor D R, Elnenaei M O, Alaghband-Zadeh J, Sherwood R A, et al. Predicting refeeding hypophosphataemia: insulin growth factor 1 (IGF-1) as a diagnostic biochemical marker for clinical practice [J]. Annals of clinical biochemistry, 2015, 52(Pt 1): 82-7.doi: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1177/0004563214523739\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Del Giudice M, Gangestad S W. Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters [J]. Brain, behavior, and immunity, 2018, 70(61-75.doi: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.bbi.2018.02.013\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Zeki S, Culkin A, Gabe S M, Nightingale J M. Refeeding hypophosphataemia is more common in enteral than parenteral feeding in adult in patients [J]. Clinical nutrition (Edinburgh, Scotland), 2011, 30(3): 365-8.doi: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.clnu.2010.12.001\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Reber E, Friedli N, Vasiloglou M F, Schuetz P, Stanga Z. Management of Refeeding Syndrome in Medical Inpatients [J]. Journal of clinical medicine, 2019, 8(12): \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/jcm8122202\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Duhm J. Glycolysis in human erythrocytes containing elevated concentrations of 2, 3-P2-glycerate [J]. Biochimica et biophysica acta, 1975, 385(1): 68-80.doi: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/0304-4165(75)90075-6\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Sharma S, Brugnara C, Betensky R A, Waikar S S. Reductions in red blood cell 2,3-diphosphoglycerate concentration during continuous renal replacment therapy [J]. Clinical journal of the American Society of Nephrology : CJASN, 2015, 10(1): 74-9.doi: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2215/cjn.02160214\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Diringer M. Neurologic manifestations of major electrolyte abnormalities [J]. Handbook of clinical neurology, 2017, 141(705-13.doi: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/b978-0-444-63599-0.00038-7\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Araujo Castro M, V\u0026aacute;zquez Mart\u0026iacute;nez C. The refeeding syndrome. Importance of phosphorus [J]. Medicina clinica, 2018, 150(12): 472-8.doi: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.medcli.2017.12.008\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e Bordej\u0026eacute; Laguna M L. [Our great forgotten, chronic respiratory sufferers] [J]. Nutricion hospitalaria, 2017, 34(Suppl 1): 38-45.doi: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.20960/nh.1238\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"acute ischemic stroke, refeeding syndrome, risk factors, NIHSS, NRS 2002","lastPublishedDoi":"10.21203/rs.3.rs-1309641/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-1309641/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground \u003c/strong\u003eAcute ischemic stroke (AIS) is more likely to develop refeeding syndrome (RFS) due to increased need for nutritional support when suffering dysfunction of consciousness and deglutition after stroke. This study aims to evaluate the occurrence, risk factors and outcomes of RFS in AIS patients.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eMethods \u003c/strong\u003eThis retrospective observational study, using the prospective stroke database from our hospital, included all consecutive AIS patients who received parenteral or enteral nutrition for more than 72 hours from January 1, 2019 to December 31, 2021. RFS was defined as occurrence of new onset hypophosphatemia within 72 hours after refeeding. Multiple logistic regression analysis was conducted to evaluate risk factors for RFS and relationship between RFS and 3-month modified Rankin Scale (mRS) score and 6-month mortility.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eResults \u003c/strong\u003eOf 1038 patients were included in the study, 154 patients (14.8 %) developed RFS. We found that baseline National Institutes of Health Stroke Scale (NIHSS), nutritional risk screening (NRS) 2002, albumin \u0026lt; 30g/L and body mass index (BMI) \u0026lt; 18.5 kg/m\u003csup\u003e2\u003c/sup\u003e were risk factors for RFS in AIS patients. Moreover, Patients in RFS group had lowerer promotion of 7-day NIHSS and RFS was independently associated with a 3-month mRS score of \u0026gt; 2 and 6-month mortility.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eConclusion \u003c/strong\u003eRFS is common in AIS patients and higher baseline NIHSS, higher NRS 2002 score, albumin \u0026lt; 30g/L and BMI \u0026lt; 18.5 kg/m\u003csup\u003e2\u003c/sup\u003e significantly increased the risk of RFS. Occurrence of RFS was significantly associated with higher 3-month mRS score and 6-month mortility.\u003c/p\u003e","manuscriptTitle":"Risk Factors and Outcomes for Refeeding Syndrome in Acute Ischemic Stroke Patients","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2022-02-04 21:02:17","doi":"10.21203/rs.3.rs-1309641/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"83f220de-bcbb-4e3b-a200-8b0ee6b95fdf","owner":[],"postedDate":"February 4th, 2022","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2022-03-08T06:59:16+00:00","versionOfRecord":[],"versionCreatedAt":"2022-02-04 21:02:17","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-1309641","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-1309641","identity":"rs-1309641","version":["v1"]},"buildId":"ehx78VzkSd0WSzXnipQa-","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}